Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bryostatin 1 - GPC Biotech

Next Previous
X
Search
Drug Profile

Bryostatin 1 - GPC Biotech

Alternative Names: BMY 45618; Bryol; NSC 339555

Latest Information Update: 25 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arizona State University
  • Developer GPC Biotech AG
  • Class Antidementias; Antidepressants; Antineoplastics; Antiparkinsonians; Behavioural disorder therapies; Macrocyclic compounds; Small molecules; Vascular disorder therapies
  • Mechanism of Action Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Chronic lymphocytic leukaemia; Graft-versus-host disease; Malignant melanoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Renal cancer

Most Recent Events

  • 15 Oct 2019 Aphios Corporation has patent protection for APH 0812 in China
  • 09 Mar 2004 Discontinued - Phase-II for Cancer in United Kingdom (Parenteral)
  • 09 Mar 2004 Discontinued - Phase-II for Chronic lymphocytic leukaemia in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top